A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2012/2013 Formulation of the Enzira vaccine in Two Groups of Healthy Volunteers: Adults (aged 18 to 59 years) and Older Adults (aged 60 years or older).

Trial Profile

A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2012/2013 Formulation of the Enzira vaccine in Two Groups of Healthy Volunteers: Adults (aged 18 to 59 years) and Older Adults (aged 60 years or older).

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs Influenza virus vaccine (Afluria) (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors Seqirus
  • Most Recent Events

    • 20 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 May 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01591837).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top